Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2022

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	June 30, 2022		June 30, 2021		June 30, 2020
Cash and cash equivalents	$	87,854	$	93,286	$	144,329
Restricted cash, included in other assets		5,000		5,000		—
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	92,854	$	98,286	$	144,329

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2022		2021		2020
Analgesic	$	15,737	$	14,684	$	8,680
Anti-Psychosis		11,790		43,720		104,934
Cardiovascular		45,376		65,987		88,576
Central Nervous System		78,325		95,115		77,256
Endocrinology		27,491		27,070		—
Gastrointestinal		51,026		67,540		73,477
Infectious Disease		28,009		67,761		73,237
Migraine		16,321		25,554		44,266
Respiratory/Allergy/Cough/Cold		8,961		9,258		11,576
Urinary		4,588		5,786		4,225
Other		41,285		35,312		35,013
Contract manufacturing revenue		11,670		20,991		24,504
Total net sales	$	340,579	$	478,778	$	545,744

Summary of products which accounted for at least 10% of total net sales

	June 30,		June 30,		June 30,
	2022		2021		2020
Product 1	6	%	12	%	10	%
Product 2	1	%	7	%	18	%

Summary of customers which accounted for at least 10% of total net sales

	June 30,		June 30,		June 30,
	2022		2021		2020
Customer A	24	%	27	%	25	%
Customer B	19	%	21	%	23	%
Customer C	14	%	12	%	11	%